Lavipharm Statistics
Total Valuation
Lavipharm has a market cap or net worth of EUR 239.54 million. The enterprise value is 267.18 million.
| Market Cap | 239.54M |
| Enterprise Value | 267.18M |
Important Dates
The next confirmed earnings date is Thursday, April 23, 2026.
| Earnings Date | Apr 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Lavipharm has 168.69 million shares outstanding.
| Current Share Class | 168.69M |
| Shares Outstanding | 168.69M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 2.21% |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 39.99.
| PE Ratio | 39.99 |
| Forward PE | n/a |
| PS Ratio | 3.83 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 44.60 |
| EV / Sales | 4.27 |
| EV / EBITDA | 20.27 |
| EV / EBIT | 28.58 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 5.06 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 15.03% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 8.94% |
| Revenue Per Employee | 221,929 |
| Profits Per Employee | 21,241 |
| Employee Count | 282 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Lavipharm has paid 2.45 million in taxes.
| Income Tax | 2.45M |
| Effective Tax Rate | 32.69% |
Stock Price Statistics
The stock price has increased by +91.38% in the last 52 weeks. The beta is 0.85, so Lavipharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.85 |
| 52-Week Price Change | +91.38% |
| 50-Day Moving Average | 1.27 |
| 200-Day Moving Average | 0.95 |
| Relative Strength Index (RSI) | 67.29 |
| Average Volume (20 Days) | 269,406 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Lavipharm had revenue of EUR 62.58 million and earned 5.99 million in profits.
| Revenue | 62.58M |
| Gross Profit | 30.31M |
| Operating Income | 9.35M |
| Pretax Income | 7.50M |
| Net Income | 5.99M |
| EBITDA | 13.18M |
| EBIT | 9.35M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
| Cash & Cash Equivalents | n/a |
| Total Debt | n/a |
| Net Cash | n/a |
| Net Cash Per Share | n/a |
| Equity (Book Value) | n/a |
| Book Value Per Share | n/a |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 3.83M |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 48.42%, with operating and profit margins of 14.94% and 9.57%.
| Gross Margin | 48.42% |
| Operating Margin | 14.94% |
| Pretax Margin | 11.99% |
| Profit Margin | 9.57% |
| EBITDA Margin | 21.06% |
| EBIT Margin | 14.94% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.02, which amounts to a dividend yield of 1.41%.
| Dividend Per Share | 0.02 |
| Dividend Yield | 1.41% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | 1.45% |
| Earnings Yield | 2.50% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 1, 2022. It was a reverse split with a ratio of 0.3333333333.
| Last Split Date | Aug 1, 2022 |
| Split Type | Reverse |
| Split Ratio | 0.3333333333 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |